ErbB3 silencing reduces osteosarcoma cell proliferation and tumor growth in vivo

Gene

Volumn 521, Issue 1, 2013, Pages 55-61

  Jullien, Nicolas ^a,b   Dieudonné, François Xavier ^a,b   Habel, Nadia ^a,b   Marty, Caroline ^a,b   Modrowski, Dominique ^a,b   Patino, Ana ^c   Lecanda, Fernando ^c   Sévère, Nicolas ^a,b   Marie, Pierre J ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

ErbB3; Osteosarcoma; Tumor growth

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; SHORT HAIRPIN RNA;

ANIMAL CELL; ARTICLE; BONE TISSUE; BONE TUMOR; CANCER CELL CULTURE; CELL DIVISION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; SOFT TISSUE METASTASIS; TISSUE MICROARRAY; TUMOR GROWTH;

ANIMALS; BASE SEQUENCE; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; OSTEOSARCOMA; RECEPTOR, ERBB-3; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE;

EID: 84876710369     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.03.031     Document Type: Article

References (49)

1. Akatsuka T., et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002, 94:1397-1404.
2. Alimandi M., et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995, 10:1813-1821.
3. Anninga J.K., et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur. J. Cancer 2004, 40:963-970.
4. Broadhead M.L., Clark J.C., Myers D.E., Dass C.R., Choong P.F. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011, 2011:959248.
5. Carraway K.L., Sweeney C. Localization and modulation of ErbB receptor tyrosine kinases. Curr. Opin. Cell Biol. 2001, 13:125-130.
6. Chen N., et al. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res. 2007, 67:6544-6548.
7. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7:505-516.
8. Contessa J.N., Abell A., Mikkelsen R.B., Valerie K., Schmidt-Ullrich R.K. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation. Breast Cancer Res. Treat. 2006, 95:17-27.
9. Cook R.S., et al. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res. 2011, 71:3941-3951.
10. De Pollack C., Renier D., Hott M., Marie P.J. Increased bone formation and osteoblastic cell phenotype in premature cranial suture ossification (craniosynostosis). J. Bone Miner. Res. 1996, 11:401-407.
11. Dieudonné F.X., Marion A., Marie P.J., Modrowski D. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice. J. Bone Miner. Res. 2012, 27:2118-2129.
12. Fisher M.C., Clinton G.M., Maihle N.J., Dealy C.N. Requirement for ErbB2/ErbB signaling in developing cartilage and bone. Dev. Growth Differ. 2007, 49:503-513.
13. Fromigué O., et al. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006, 13:1845-1856.
14. Fromigué O., Hamidouche Z., Marie P.J. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J. Biol. Chem. 2008, 283:30549-30556.
15. Geryk-Hall M., Hughes D.P. Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions. Curr. Oncol. Rep. 2009, 11:446-453.
16. Himelstein B.P. Osteosarcoma and other bone cancers. Curr. Opin. Oncol. 1998, 10:326-333.
17. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8933-8938.
18. Hughes D.P., Thomas D.G., Giordano T.J., Baker L.H., McDonagh K.T. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004, 64:2047-2053.
19. Hughes D.P., Thomas D.G., Giordano T.J., McDonagh K.T., Baker L.H. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr. Blood Cancer 2006, 46:614-623.
20. Hynes N.E., Horsch K., Olayioye M.A., Badache A. The ErbB receptor tyrosine family as signal integrators. Endocr. Relat. Cancer 2001, 8:151-159.
21. Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat. Res. 2009, 152:239-262.
22. Jullien N., Maudinet A., Leloutre B., Ringe J., Haupl T., Marie P.J. Downregulation of ErbB3 By Wnt3a contributes to Wnt-induced osteoblast differentiation in mesenchymal cells. J. Cell. Biochem. 2012, 113:2047-2056.
23. Khanna C., Prehn J., Yeung C., Caylor J., Tsokos M., Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin. Exp. Metastasis 2000, 18:261-271.
24. Kobayashi M., Iwamatsu A., Shinohara-Kanda A., Ihara S., Fukui Y. Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. Oncogene 2003, 22:1294-1301.
25. Kubo T., et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008, 112:2119-2129.
26. Lafky J.M., Wilken J.A., Baron A.T., Maihle N.J. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim. Biophys. Acta 2008, 1785:232-265.
27. Li Y.G., Geng X. A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma. Eur. J. Cancer Care (Engl.) 2010, 19:313-316.
28. Lin S.H., et al. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin. Cancer Res. 2008, 14:3729-3736.
29. MacEwen E.G., et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J. Cell. Biochem. 2004, 92:77-91.
30. McQueen P., Ghaffar S., Guo Y., Rubin E.M., Zi X., Hoang B.H. The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev. Anticancer Ther. 2011, 11:1223-1232.
31. Mosesson Y., Yarden Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin. Cancer Biol. 2004, 14:262-270.
32. Naidu R., Yadav M., Nair S., Kutty M.K. Expression of c-erbB3 protein in primary breast carcinomas. Br. J. Cancer 1998, 78:1385-1390.
33. Onda M., et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996, 77:71-78.
34. Rajkumar T., Stamp G.W., Hughes C.M., Gullick W.J. c-erbB3 protein expression in ovarian cancer. Clin. Mol. Pathol. 1996, 49:M199-M202.
35. Rakesh Kumar V., Gupta N., Kakkar N., Sharma S.C. Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma. J. Cancer Res. Ther. 2006, 2:20-23.
36. Schaefer K.L., et al. Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue. Neoplasia 2006, 8:613-622.
37. Schoeberl B., et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 2010, 70:2485-2494.
38. Sévère N., et al. Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis. J. Bone Miner. Res. 2012, 27:2108-2117.
39. Sheng Q., et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010, 17:298-310.
40. Sithanandam G., Anderson L.M. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008, 15:413-448.
41. Sithanandam G., Smith G.T., Masuda A., Takahashi T., Anderson L.M., Fornwald L.W. Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway. Carcinogenesis 2003, 24:1581-1592.
42. Sithanandam G., Fornwald L.W., Fields J., Anderson L.M. Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene 2005, 24:1847-1859.
43. Soler M., et al. HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. Int. J. Cancer 2009, 125:2565-2575.
44. Tang N., Song W.X., Luo J., Haydon R.C., He T.C. Osteosarcoma development and stem cell differentiation. Clin. Orthop. Relat. Res. 2008, 466:2114-2130.
45. Thomas D.G., Giordano T.J., Sanders D., Biermann J.S., Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin. Cancer Res. 2002, 8:788-793.
46. Vakar-Lopez F., et al. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J. Pathol. 2004, 203:688-695.
47. Xue C., et al. ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res. 2006, 66:1418-1426.
48. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
49. Zhang H., et al. ErbB receptors: from oncogenes to targeted cancer therapies. J. Clin. Invest. 2007, 117:2051-2058.